This book provides an update on heterocyclic compounds that serve as key components of anti-cancer agents administered in pre-clinical settings. Many of the compounds highlighted in the book are being actively investigated for the bioactive properties against a range of cancer cell lines. There is potential for heterocyclic compounds to design agents that can target specific molecules to treat different types of cancers. Chapters are contributed by experts in pharmaceutical chemistry and are written to give a general overview of the topic to readers involved in all levels of research and decision-making in pharmaceutical chemistry and anti-cancer drug design.
Part 2 of the book set covers these topics:
- Anticancer targets for heterocyclic lead compounds
- Coumarin hybrids for cancer treatments
- Progress in nitrogen and sulphur-based heterocyclic compounds for their anticancer activity
- Imidazole as an anticancer heterocyclic ring
- Morpholine for profiling anticancer lead compounds
- Natural products as anticancer agents
Table of Contents
- Foreword
- Preface
- List of Contributors
- Shweta Sharma, Mymoona Akhter and Rajesh Kumar Singh
- Introduction
- Various Heterocyclic Anticancer Drug Targets
- Heterocyclic Drugs as Protein Deacetylation Inhibitors
- Histone Deacetylase (Hdac) Inhibitors
- Sirtuin 1 Inhibitors
- Heterocyclic Drugs as Inhibitors of Cellular Proliferation
- Tubulin Inhibitors
- Topoisomerase Expression Inhibitors
- Kinase Inhibitors
- Mtor Inhibitors
- Braf Inhibitors
- Nf-Kß Inhibitors
- Inhibition of Jak/Stat Signalling Pathway
- H Eterocyclic Drugs as Inhibitors of Multidrug Resistance (Mdr) 21
- Atp- Binding Cassette Transporter G2 (Abcg2) Inhibitors
- P-Glycoprotein Inhibitors
- Heterocyclic Drugs as P53 Degradation Inhibitors
- Inhibition of Oncoprotein
- Probable Drug Targets for Future Development
- Cathepsin-K Inhibitors
- Dpp-Iv Inhibitor
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Rohit Bhatia, Amandeep Singh, Bhupinder Kumar and Ravindra K. Rawal
- Introduction
- Concept of Coumarin Hybrid Molecules Against Cancer
- Coumarin Hybrids as Aromatase Inhibitors
- Coumarin Hybrids as Topoisomerase Inhibitors
- Coumarin Hybrids as Caspase Activators and Apoptosis Inducers
- Coumarin Hybrids as Selective Estrogen Receptor Degraders (Serds)
- Coumarin Hybrids as Tubulin Targeting Agents
- Coumarin Hybrids as Protein Kinase Inhibitors (Pki)
- Coumarin Hybrids as Cdk Inhibitor
- Coumarin Hybrids as Histone Deacetylase Inhibitors (Hdi)
- Miscellaneous
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Preeti Koli and Rajesh K. Singh
- Introduction
- Pyrrole
- Chemistry of Pyrrole
- Anticancer Activity of Pyrrole Derivatives
- Quinazoline
- Chemistry of Quinazoline
- Anticancer Activity of Quinazoline Derivatives
- 1st Generation Reversible Egfr Inhibitor
- 2nd Generation Irreversible Egfr Inhibitor
- Thiadiazole
- Chemistry of Thiadiazole
- Anticancer Activity of Thiadiazole Derivatives
- Quinoline
- Chemistry of Quinoline
- Anticancer Activity of Quinoline Derivatives
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgement
- References
- Ashwani K. Dhingra, Bhawna Chopra, Akram Sidhu, Kumar Guarve and Ashish Gupta
- Introduction
- Chemistry of Imidazole
- Imidazole Analogs Possessing Anticancer Potential
- Imidazoles as Antiangiogenic Agents
- Imidazoles as Focal Adhesion Kinase Enzyme Inhibitors
- Imidazoles as Anti-Proliferative Agents
- Imidazoles as Cyp26A1 Enzyme Inhibitors
- Imidazoles as Topoisomerase Inhibitors
- Imidazoles as Rapid Accelerated Fibrosarcoma (Raf) Kinase Inhibitors
- Imidazoles as Microtubule Destabilizing Anticancer Agents
- Imidazoles as Chk-1 and Chk-2 Inhibitors
- Miscellaneous Biological Targets of Imidazoles
- Market Status of Imidazole-Based Anticancer Drugs
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgement
- References
- Archana Kumari and Rajesh K. Singh
- Introduction
- Different Strategies for Morpholine Ring Synthesis
- Natural and Synthetic Sources of Morpholine
- Role of Morpholine Ring in Modulating Pharmacokinetic
- Parameters
- Improvement of Pharmacokinetic Properties of the Morpholine
- Ring
- Anticancer Potential of Morpholine Derivatives
- Morpholine Derivatives as Mtor Inhibitors
- Morpholine Derivatives as Phosphoinositide 3-Kinase (Pi3K) Inhibitors
- Morpholine Derivatives as Potent Tnf-A/Il-2 Dual Inhibitor
- Morpholine Derivatives as Dual Pi3K and Mtor Inhibitors
- Morpholine Derivatives as Potent Inhibitor of Dihydrofolate Reductase Enzyme
- Morpholine Derivatives as Caspases Enzyme Inhibitors
- Miscellaneous Drugs
- Drugs Under Clinical Trial
- Conclusion and Future Perspectives
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Anurag Chaudhary, Kalpana Singh, Nishant Verma and Alok Sharma
- Introduction
- A Novel Approach of Various Phytochemicals Against Cancer
- Berberine
- Vinca Alkaloids
- Taxanes
- Colchicine
- Combretastatin
- Ursolic Acid
- Chalcone
- Taccalonanolide
- Capsaicin
- Kaempferol
- Mushrooms Dietary Fibers
- Mushroom Proteins
- ß-Elemene
- Oroxylin Flavone
- Different Strategies for the Development of Anticancer
- Phytochemicals
- Future Prospects
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Subject Index
Contributors
- Rajesh Kumar Singh
